Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020.

Lortholary O; Fernandez-Ruiz M; Baddley JW; Manuel O; Mariette X; Winthrop KL

doi:10.1136/annrheumdis-2020-217092

Back

Journal article

Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020.

Lortholary O Paris University, Necker Pasteur Center for Infectious Diseases and Tropical Medicine, IHU Imagine, Necker Enfants malades University Hospital, APHP, Paris, France olivier.lortholary@aphp.fr.
Fernandez-Ruiz M Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), School of Medicine, Universidad Complutense, Madrid, Spain.
Baddley JW University of Maryland School of Medicine, Division of Infectious Diseases, Baltimore, Maryland, USA.
Manuel O Infectious Diseases Service and Transplantation Center, University Hospital and University of Lausanne, Lausanne, Switzerland.
Mariette X Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux universitaires Paris-Sud - Hôpital Bicêtre, Le Kremlin Bicêtre, France.
Winthrop KL Oregon Health Sciences University, Portland, Oregon, USA.

2020-09-23

Published in:

Annals of the rheumatic diseases. - 2020

English Biological therapies have improved the outcomes of several major inflammatory, autoimmune and also neoplastic disorders. Those directed towards cytokines or other soluble mediators, cell-surface molecules or receptors or various components of intracellular signalling pathways may be associated with the occurrence of infections whose diversity depends on the particular immune target. In this context and following a keynote lecture given by one of us at the European League Against Rheumatism meeting on June 2018, a multidisciplinary group of experts deeply involved in the use of targeted and biological therapies in rheumatoid and psoriatic arthritis decided to summarise their recent vision of the immunological basis and epidemiology of infections occurring during targeted and biological therapies, and provide useful indications for their management and prevention.

Language